Satellos Bioscience Announces Results of Annual Meeting of Shareholders

Satellos Bioscience Inc. held its Annual Meeting of Shareholders on June 17, 2026, with 55.3% shareholder participation. All nine director nominees were elected with strong support, with most receiving over 99% approval votes. PricewaterhouseCoopers LLP was re-appointed as the company's auditor. The clinical-stage biotech company continues advancing SAT-3247, its lead candidate for treating degenerative muscle diseases including DMD, with Phase II trials (BASECAMP in pediatrics and TRAILHEAD in adults) progressing on schedule.